Amount Raised
$57.7 Million
Round Type
Series E
HoustonManufacturingBiotechnologyHealthcareHealth CareMedicalMedical DeviceInvestors
Description
Procyrion, Inc. announced the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. The funds will be used to support the ongoing DRAIN-HF pivotal IDE trial evaluating the Aortix percutaneous mechanical circulatory support (pMCS) device in patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS), as well as internal programs to improve product manufacturability and prepare for commercialization. The round was led by Fannin Partners in partnership with new and existing family/multi-family office investors.
Who to call at Procyrion, and when
A new round usually means Procyrion is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Procyrion raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Procyrion, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Procyrion. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Procyrion raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Procyrion raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.